Speaker:

Gabriella Reardon

Learning Objectives:

• Compare and contrast the published 2025 AHA/ACC Hypertension treatment guidelines with the 2017 guidelines
• Critique the primary literature that implemented the 2025 guidelines revisions, evaluating its impact on therapeutic strategies
• Discuss aprocitentan’s place in therapy and supporting clinical data

Disclosure:
Gabriella has no relevant financial relationships to disclose